Cristina Falci
Research Subjects
Research Interests
Cristina Falci has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Gaia Griguolo
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
9 shared publications - Valentina Guarneri
Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy
9 shared publications - Federica Miglietta
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Division of Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy
8 shared publications - Maria Vittoria Dieci
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
8 shared publications - Carlo Alberto Giorgi
Istituto Oncologico Veneto 2 Division of Oncology 2, IRCCS, Padova, Italy
7 shared publications - Christine Hodgdon
GRASP, Baltimore, Maryland
7 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Cumulative incidence curves for diagnosis of brain metastases (A), diagnosis of symptomatic brain metastases (B), and diagnosis of asymptomatic brain metastases (C) according to brain screening practice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Cumulative incidence curves for diagnosis of brain metastases (A), diagnosis of symptomatic brain metastases (B), and diagnosis of asymptomatic brain metastases (C) according to brain screening practice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinical characteristics at brain metastasis diagnosis and first treatments received (locoregional and systemic) after brain metastasis diagnosis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinical characteristics at brain metastasis diagnosis and first treatments received (locoregional and systemic) after brain metastasis diagnosis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinicopathologic characteristics at breast cancer diagnosis and at mBC diagnosis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Clinicopathologic characteristics at breast cancer diagnosis and at mBC diagnosis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose:According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC.Experimental Design:Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis.Results:Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073).Conclusions:Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose:According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC.Experimental Design:Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis.Results:Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073).Conclusions:Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
OS after brain metastasis diagnosis according to brain screening practice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
OS after brain metastasis diagnosis according to brain screening practice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Flow diagram of the study cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Flow diagram of the study cohort.
- Open Access
- 10 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (5)
Long-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study
Background: Isolated locoregional relapse (ILRR) after curative treatment for early breast cancer (BC) is associated with poor prognosis. Treatment strategies are poorly standardized. We aimed at exploring prognostic factors and long-term outcomes of ILRR. Patients and methods: Overall, 1070 patients diagnosed with stage I-III BC between 2000 and 2007 were identified from a large mono-institutional dataset, with long follow up. Among these, 66 patients (6%) presented an ILRR as first BC event and 33% subsequently presented a distant recurrence (DR) (22/66). Results: In the overall study cohort, patients with ILRR presented a significantly higher risk of DR compared to those without ILRR (P < .001). However, while being diagnosed with a DR was significantly associated with a worse overall survival (OS), ILRR was not. In the subgroup of patients with ILRR (N = 66), more advanced nodal status at initial diagnosis and HER2-positivity on the ILRR were significantly associated with worse distant relapse-free interval (DRFI) post-ILRR and worse OS post-ILRR. Moreover, switching from HR+ primary BC to HR− ILRR was associated with worse OS post-ILRR. In multivariate analyses, nodal involvement at primary diagnosis remained independently associated with both DRFI and OS post-ILRR, while HER2+ ILRR was independently associated with worse OS post-ILRR. Conclusion: Patients diagnosed with ILRR after curative treatment for primary BC are at higher risk of subsequent DR, highlighting the need for prompt diagnosis and treatment of ILRR. Moreover, biological recharacterization of ILRR provides potential key prognostic and predictive factors, such as HR loss, allowing personalization of treatment and follow-up after ILRR.
- 10 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (5)
Open AccessLong-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study
Background: Isolated locoregional relapse (ILRR) after curative treatment for early breast cancer (BC) is associated with poor prognosis. Treatment strategies are poorly standardized. We aimed at exploring prognostic factors and long-term outcomes of ILRR. Patients and methods: Overall, 1070 patients diagnosed with stage I-III BC between 2000 and 2007 were identified from a large mono-institutional dataset, with long follow up. Among these, 66 patients (6%) presented an ILRR as first BC event and 33% subsequently presented a distant recurrence (DR) (22/66). Results: In the overall study cohort, patients with ILRR presented a significantly higher risk of DR compared to those without ILRR (P < .001). However, while being diagnosed with a DR was significantly associated with a worse overall survival (OS), ILRR was not. In the subgroup of patients with ILRR (N = 66), more advanced nodal status at initial diagnosis and HER2-positivity on the ILRR were significantly associated with worse distant relapse-free interval (DRFI) post-ILRR and worse OS post-ILRR. Moreover, switching from HR+ primary BC to HR− ILRR was associated with worse OS post-ILRR. In multivariate analyses, nodal involvement at primary diagnosis remained independently associated with both DRFI and OS post-ILRR, while HER2+ ILRR was independently associated with worse OS post-ILRR. Conclusion: Patients diagnosed with ILRR after curative treatment for primary BC are at higher risk of subsequent DR, highlighting the need for prompt diagnosis and treatment of ILRR. Moreover, biological recharacterization of ILRR provides potential key prognostic and predictive factors, such as HR loss, allowing personalization of treatment and follow-up after ILRR.
- Open Access
- 13 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (9) , OF1-OF9
Proactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose: According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC. Experimental Design: Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis. Results: Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073). Conclusions: Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- 13 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (9) , OF1-OF9
Open AccessProactive Brain Screening Using Contrast-Enhanced Brain CT Scans in HER2+ Metastatic Breast Cancer
Purpose: According to recent EANO-ESMO guidelines, proactive brain imaging can be considered in asymptomatic patients with HER2+ metastatic breast cancer (mBC) because of high risk of developing brain metastases. However, optimal imaging modality and timing remain unclear. We retrospectively assessed the impact of contrast-enhanced CT screening on symptomatic brain metastases in patients with HER2+ mBC. Experimental Design: Consecutive patients newly diagnosed with HER2+ mBC treated with trastuzumab–pertuzumab plus taxane (2014–2024) were retrospectively identified. Brain screening was defined as at least one contrast-enhanced brain CT scan per year without neurologic symptoms during the first 2 years after diagnosis. Results: Among 148 identified patients, 73 underwent brain screening and 75 did not. The median number of annual brain CT scans during the first 2 years was 2.0 (IQR, 1.2–2.5) and 0.0 (IQR, 0–0.5) in the screening and nonscreening groups, respectively. Thirty (20.3%) patients developed brain metastases during the first 2 years. The cumulative brain metastasis incidence was significantly higher in patients undergoing screening (30.6% vs. 12.3%, Gray’s P = 0.004), but symptomatic brain metastases were significantly lower in patients undergoing screening (0% vs. 9.5%, Gray’s P = 0.012). Patients undergoing screening had better preserved performance status at brain metastasis diagnosis (P = 0.002) and a numerical trend toward fewer brain metastases (P = 0.057). Treatment patterns after brain metastasis diagnosis were similar, although whole-brain radiotherapy was used less often in the screening group (14.3% vs. 44.4%, P = 0.073). Conclusions: Brain screening with CT scans was associated with fewer symptomatic brain metastases and better performance status at brain metastasis diagnosis, supporting proactive imaging in HER2+ mBC. Prospective studies are warranted to define optimal timing and imaging modalities.
- 15 February 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (4_Suppleme) , P1-12
Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastases
Background: Brain metastases (BM) are a serious relatively common complication of breast cancer (BC). We evaluated prognostic factors for survival after diagnosis of BM from BC in a contemporary cohort of pts. Methods:Pts diagnosed with BM from BC between 1999 and march 2016 and treated at the Istituto Oncologico Veneto of Padua were evaluated. Overall survival (OS) was defined as time from BM diagnosis to death or last follow-up. Pts were classified in 4 categories according to the breast cancer-specific Graded Prognostic Assessment (GPA) index according to validated criteria (Sperduto et al, 2012), based on age, Karnofsky Performance Status (KPS) and BC phenotype. Cox proportional models were used to calculate HR and 95% CI. Results: 199 pts were identified. Median age at BM diagnosis was 56 yrs (range 28-84). Tumor phenotype distribution was as follows: triple negative (TN, 20.1%), hormone receptor (HR)-HER2+ (16.8%), HR+HER2+ (24.0%) and HR+HER2- (39.1%). Median time to BM diagnosis was 48.9 months (range 0-327), with significant differences according to tumor phenotype (median 27.3, 31.8, 46.1 and 55.2 months in TN, HR-HER2+, HR+HER2+, HR+HER2-, respectively, p=0.009). With respect to OS, no significant difference was observed across tumor phenotypes, with TN patients experiencing the worse outcome (median: 4.7, 7.7, 11.0 and 6.2 months in TN, HR-HER2+, HR+HER2+, HR+HER2-, p=0.187). The breast-specific GPA index, which combines tumor phenotype with patient-related features, was significantly associated with OS (Table). The number of local treatment received (radiotherapy, either whole brain or stereotactic, or neurosurgery) and the administration of systemic treatment after BM diagnosis were significantly associated with better OS (Table). Patients in the less favorable GPA category (GPA index Conclusions: Patient-related features, tumor phenotype and multimodal treatments all independently contribute to modulate the prognosis of pts with BM from BC. Citation Format: Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Conte P, Guarneri V. Factors related to the prognosis of breast cancer patients after the development of brain metastases [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-12-06.
- 15 February 2017
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (4_Suppleme) , P1-12
Abstract P1-12-06: Factors related to the prognosis of breast cancer patients after the development of brain metastases
Background: Brain metastases (BM) are a serious relatively common complication of breast cancer (BC). We evaluated prognostic factors for survival after diagnosis of BM from BC in a contemporary cohort of pts. Methods:Pts diagnosed with BM from BC between 1999 and march 2016 and treated at the Istituto Oncologico Veneto of Padua were evaluated. Overall survival (OS) was defined as time from BM diagnosis to death or last follow-up. Pts were classified in 4 categories according to the breast cancer-specific Graded Prognostic Assessment (GPA) index according to validated criteria (Sperduto et al, 2012), based on age, Karnofsky Performance Status (KPS) and BC phenotype. Cox proportional models were used to calculate HR and 95% CI. Results: 199 pts were identified. Median age at BM diagnosis was 56 yrs (range 28-84). Tumor phenotype distribution was as follows: triple negative (TN, 20.1%), hormone receptor (HR)-HER2+ (16.8%), HR+HER2+ (24.0%) and HR+HER2- (39.1%). Median time to BM diagnosis was 48.9 months (range 0-327), with significant differences according to tumor phenotype (median 27.3, 31.8, 46.1 and 55.2 months in TN, HR-HER2+, HR+HER2+, HR+HER2-, respectively, p=0.009). With respect to OS, no significant difference was observed across tumor phenotypes, with TN patients experiencing the worse outcome (median: 4.7, 7.7, 11.0 and 6.2 months in TN, HR-HER2+, HR+HER2+, HR+HER2-, p=0.187). The breast-specific GPA index, which combines tumor phenotype with patient-related features, was significantly associated with OS (Table). The number of local treatment received (radiotherapy, either whole brain or stereotactic, or neurosurgery) and the administration of systemic treatment after BM diagnosis were significantly associated with better OS (Table). Patients in the less favorable GPA category (GPA index Conclusions: Patient-related features, tumor phenotype and multimodal treatments all independently contribute to modulate the prognosis of pts with BM from BC. Citation Format: Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Conte P, Guarneri V. Factors related to the prognosis of breast cancer patients after the development of brain metastases [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-12-06.
- Open Access
- 1 December 2013
- Published by Elsevier in Experimental Gerontology
- Vol. 48 (12) , 1436-1442
Immune senescence and cancer in elderly patients: Results from an exploratory study
- 1 December 2013
- Published by Elsevier in Experimental Gerontology
- Vol. 48 (12) , 1436-1442
Open AccessImmune senescence and cancer in elderly patients: Results from an exploratory study